FS Development (NASDAQ:FSDC) showed in an 8-K filing that its shareholders approved its combination with biotech firm Gemini Therapeutics, when at a special meeting earlier today only 100 shares redeemed.
This low redemption number is not too much of a surprise as the company opened at $13.06 ahead of the vote, and its share price has never dipped below its pro rata trust value. The filing did not include a timeline for the transaction’s close, but it should not be far off. GMNI is anticipated to be the new symbol for the share.
FS Development initially announced its $265.6 million deal with Gemini on October 15. Gemini is a clinical stage precision medicine company developing treatments for age-related macular degeneration (AMD) by developing drugging strategies that are matched to specific genetic mutations.
All measures on the special meeting’s ballot passed by wide margins with about 75.8% of shares participating. About 19% of shares voted against certain governance measures giving additional powers to the Board, however. For a full list of proposals and vote tallies, click HERE.
ADVISORS
- Jefferies LLC and SVB Leerink acted as co-lead private placement agents for FS Development Corp.
- Jefferies LLC also acted as lead financial and capital markets advisor to FS Development Corp.
- Goldman Sachs & Co. LLC acted as lead financial advisor to Gemini in the transaction.
- Stifel acted as additional capital markets advisor to Gemini.
- Goodwin Procter LLP acted as legal counsel to Gemini.
- White & Case LLP acted as legal counsel to FS Development Corp.
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....